Chimeric antigen receptor transgenic T cell (CAR-T) therapy targeting the CD19 antigen was approved for relapsed/refractory acute lymphocytic leukemia in the United States in 2017 and in Japan in 2019. Despite the excellent efficacy of CAR-T therapy, the relapse rate is about 50%. To reduce this rate, it will be important to examine predictive factors for relapse and which patients should receive hematopoietic cell transplantation. In addition, as the high cost of CAR-T cells has become a financial toxicity that threatens the health insurance system in many countries, development of less expensive CAR-T products using non-viral vectors is also underway.
Keyphrases
- acute lymphoblastic leukemia
- health insurance
- end stage renal disease
- acute myeloid leukemia
- affordable care act
- chronic kidney disease
- induced apoptosis
- ejection fraction
- newly diagnosed
- cancer therapy
- bone marrow
- liver failure
- peritoneal dialysis
- free survival
- diffuse large b cell lymphoma
- oxidative stress
- drug delivery
- cell cycle arrest
- nk cells
- hepatitis b virus
- mesenchymal stem cells
- smoking cessation
- cell therapy
- pi k akt